Evidence map›Paper›PMID 40838947›Full record

ArticleOncoimmunology2025

Differential distribution of immune checkpoints across molecular subtypes of colorectal cancer.

Sofia Edin, Björn Gylling, Xingru Li, Åsa Stenberg, Anna Löfgren-Burström, Bethany van Guelpen, Agnes Ling, Ingrid Ljuslinder, Richard Palmqvist

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sofia EdinDepartment of Medical Biosciences, Umeå University, Umeå, Sweden.
Björn GyllingDepartment of Medical Biosciences, Umeå University, Umeå, Sweden.
Xingru LiDepartment of Medical Biosciences, Umeå University, Umeå, Sweden.
Åsa StenbergDepartment of Medical Biosciences, Umeå University, Umeå, Sweden.
Anna Löfgren-BurströmDepartment of Medical Biosciences, Umeå University, Umeå, Sweden.
Bethany van GuelpenDepartment of Diagnostics and Intervention, Umeå University, Umeå, Sweden.
Agnes LingDepartment of Medical Biosciences, Umeå University, Umeå, Sweden.
Ingrid LjuslinderDepartment of Diagnostics and Intervention, Umeå University, Umeå, Sweden.
Richard PalmqvistDepartment of Medical Biosciences, Umeå University, Umeå, Sweden.ORCID 0000-0002-9933-2843

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent introduction of immune checkpoint inhibitor therapy has significantly improved outcomes for patients with colorectal cancer (CRC). The most pronounced clinical benefits were observed in patients with immunogenic microsatellite instable (MSI)/deficient MMR (dMMR) tumors. However, emerging evidence indicates that a subset of patients with microsatellite stable tumors may also respond to therapy. Finding predictive markers to identify these patients is critical. In this study, we analyzed the immunohistochemical expression of immune checkpoints CTLA-4, PD-1, and PD-L1 using multispectral imaging in 151 CRC patients with defined molecular characteristics. Consistent with prior reports, MSI tumors had higher levels of all immune checkpoints analyzed than microsatellite stable tumors. Notably, distinct patterns of immune checkpoint expression were associated with

Indexed as

Biomarkers, TumorColorectal NeoplasmsImmune Checkpoint ProteinsAdultAgedAged, 80 and overB7-H1 AntigenCTLA-4 AntigenFemaleHumansImmune Checkpoint InhibitorsMaleMicrosatellite InstabilityMiddle AgedMutationProgrammed Cell Death 1 ReceptorB7-H1 AntigenBiomarkers, TumorBRAF protein, humanCD274 protein, humanCTLA-4 AntigenCTLA4 protein, humanImmune Checkpoint InhibitorsImmune Checkpoint ProteinsKRAS protein, humanPDCD1 protein, humanProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)BRAFcolorectal cancerimmune checkpointsimmunotherapyKRAS

Identifiers

PMID40838947
PMCPMC12372490

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.